Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2013
  • Online publication date: June 2013

Chapter 5 - Peripheralsurgical and movement modification therapies for movement disorders

from Section 2 - Intervention options


1. NaumannM, SoY, ArgoffCE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1707–14.
2. GellerBD, HallettM, RavitsJ. Botulinum toxin therapy in hemifacial spasm: clinical and electrophysiological studies. Muscle & Nerve 1989;12:716–22.
3. DykstraDD, SidiAA. Treatment of Detrusor Sphincter Dyssinergia with botulinum A toxin: a double blind study. Arch Phys Med Rehabil 1990:71:24–6.
4. BlackieJD, LeesAJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol, Neurosurg Psychiatr 1990;53:640–3.
5. BlitzerA, BrinMF. Laryngeal dystonia a series with botulinum toxin therapy. Ann Otol Rhinol Laryngol 1991;100:85–9.
6. CuiM, KhanijouS, RubinoJ, AokiKR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125–33.
7. FreundBJ, SchwartzM. Treatment of chronic cervical associated headache with botulinum toxin A: a pilot study. Headache 2000;40:231–6.
8. Lang, A. Botulinum toxin type A for the management of cervicothoracic and cervicobrachial pain: treatment rationale and open label results in 25 patients. American Journal of Pain Management, 2004;14:13–23.
9. BhaktaBB, CozensJA, BamfordJM, ChamberlainMA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996;61:30–5.
10. FockJ, GaleaMP, StillmanBC, RawickiB, ClarkM. Functional outcome following botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury. Brain Injury 2004;18:57–63.
11. SimpsonDM, AlexanderDN, O’BrienCF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo controlled trial. Neurology 1996;46:1306–10.
12. Al-KhodairyAT, GobeletC, RossierAB. Has botulinum toxin type A a place in the treatment of spasticity in spinal cord injury patients?Spinal Cord 1998;36:854–8.
13. BarnesM. Botulinum toxin – mechanisms of action and clinical use in spasticity. J Rehabil Med 2003;41:S56–9.
14. RossettoO. How botulinum toxins work. In: MooreAP, NaumannNP, eds. Handbook of Botulinum Toxin Treatment, 2nd edn. Oxford: Blackwell Scientific Press, 2003; 9–27.
15. DollyJO, AokiKR. The structure and mode of action of different botulinum toxins. Eur J Neurol 2006;13:S(4)1–9.
16. GazeraniP, PedersonNS, StaahlC, DrewesA, Arendt-NielsenL. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009;141:60–9.
17. BrinMF, LyonsKE, DoucetteJ, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001;56:1523–8.
18. JankovicJ, OrmanJ. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987;37:616–23.
19. TsuiJK, EisenA, StoesslAJ, CalneS, CalneDB. Doubleblind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245–7.
20. FruehBR, FeltDP, WojnoTH, MuschDC. Treatment of blepharospasm with botulinum toxin: a preliminary report. Arch Ophthalmol 1984;102:1464–8.
21. FahnS. Concept and classification of dystonia. Adv Neurol 1988;50:1–8.
22. SangerTD, DelgadoMR, Gaebler-SpiraD, et al. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003;111:89–97.
23. Aoki, KR, RanouxD, WisselJ. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Nuerol 2006;13:S(4)10–19.
24. de PaivaA, MeunierFA, MolgoJ, AokiKR, DollyJO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96:3200–5.
25. NovakI, CampbellL, BoyceM, FungVS. Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement. Eur J Neurol 2010;17:S(2)94–108.
26. AdamOR, JankovicJ. Treatment of dystonia. Parkinsonism Relat Disord, 2007;13:S362–8.
27. SheffieldJK, JankovicJ. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson’s disease. Expert Rev Neurotherapeutics, 2007;7:637–47.
28. KenneyC, JankovicJ. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 2008;115:585–91.
29. TsuiJK, BhattM, CalneS, CalneDB. Botulinum toxin in the treatment of writer’s cramp: a double blind study. Neurology 1993;43:183–5.
30. SchueleS, JabuschHC, LedermanRJ, AltenmullerE. Botulinum toxin injections in the treatment of musician’s dystonia. Neurology 2005;64:341–3.
31. DeuschlG, BainP, BrinM. Consensus statement of the Movement Disorder Society on tremor. Ad Hoc Scientific Committee. Mov Disord 1998;13:3–23.
32. JankovicJ. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009;8:844–56.
33. JankovicJ, SchwartzK, ClemenceW, AswadA, MordauntJ. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 1996;11:250–6.
34. GraciesJM, Simpson, D. Spastic dystonia. In BrinMF, ComellaC, JankovicJ, eds. Dystonia: Etiology, Clinical Features, and Treatment. Philadelphia: Lippincott, Williams and Wilkins, 2004, p. 195.
35. CordivariC, MisraVP, CataniaS, LeesAJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord 2001;16:907–13.
36. SheeanG, LanninNA, Turner-StokesL, et al. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol 2010;17:S(2)74–93.
37. OlverJ, EsquenaziA, FungVS, et al. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol 2010;17:S(2)57–73.
38. PacchettiC, AlbaniG, MartignoniE, et al. “Off” painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord 1995;10:333–6.
39. LimousinP, MeminB, PollakP. Treatment of dystonia occurring in parkinsonian syndromes by botulinum toxin. Eur J Neurol 1997;37:66–7.
40. Denny-BrownD. The nature of apraxia. J Nerv Ment Dis 1958;126:9–31.
41. GurevicT, PeretzC, MooreO, WeizmannN, GiladiN. The effect of injecting botulinum toxin type A into the calf muscles on freezing of gait in Parkinson’s disease: a double blind placebo-controlled pilot study. Mov Disord 2007;22:880–3.
42. WielerM, CamicoliR, JonesCA, MartinWR. Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology 2005;65:626–8.
43. FernandezHH, LammonMC, TrieschmannME, FriedmanJH. Botulinum toxin type B for gait freezing in Parkinson’s disease. Med Sci Monit 2004;10:282–4.
44. SchneiderSA, EdwardsMJ, GrillSE, et al. Adult-onset primary lower limb dystonia. Mov Disord 2006;21:767–71.
45. SchneiderSA, EdwardsMJCordivariC, MacleodWN, BhatiaKP. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson s disease. Mov Disord 2006;21:1722–4.
46. KhaliliAA, HarmelMJ, ForsterS, BentonJG. Management of spasticity by selective peripheral nerve block with dilute phenol solutions in clinical rehabilitation. Arch Phys Med Rehabil 1964;45:513–19.
47. WoodKM. The use of phenol as a neurolytic agent: a review. Pain 1978;5:205–29.
48. FelsenthalG. Pharmacology of phenol in peripheral nerve blocks: a review. Arch Phys Med Rehab 1974;55:13–16.
49. GoochJL, PattonCP. Combining botulinum toxin and phenol to manage spasticity in children. Arch Phys Med Rehabil 2004;85:1121–4.
50. LeeJ, LeeYS. Percutaneous chemical nerve block with ultrasound-guided intraneural injection. Eur Radiol 2008;18:1506–12.
51. KirazliY, OnAY, KismaliB, AksitR. Comparison of phenol block and botulinus toxin in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil 1998:77;510–15.
52. GarlandDE, LucieRS, WatersRLCurrent uses of open phenol nerve block for adult acquired spasticity. Clin Orthop Rel Res 1982;165:217–22.
53. KeenanMA, TomasES, StoneL, GerstenLM. Percutaneous phenol block of the musculocutaneous nerve to control elbow flexor spasticity. J Hand Surg Am 1990;15:340–6.
54. BrunoG. Intrathecal alcohol block experiences on 41 cases. Paraplegia 1975;12:305–9.
55. JangSH, AhnSH, ParkSM, et al. Alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle to treat ankle spasticity in patients with hemiplegic stroke. Arch Phys Med Rehabil 2004;85:506–8.
56. Rawicki, H. Treatment of cerebral origin spasticity with continuous intrathecal baclofen delivered via an implantable pump: long term follow-up and review of 18 patients. J Neurosurg 1999;91:733–6.
57. MeythalerJM, Guin-RenfroeS, BrunnerRC, HadleyMN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 2001;32:2099–109.
58. WardAB. Long-term modification of spasticity. J Rehabil Med 2003;41:S60–5.
59. KorenkovAI, NiendorfWR, DarwishN, GlaeserE, GaabMR. Continuous intrathecal infusion of baclofen in patients with spasticity caused by spinal cord injuries. Neurosurg Rev 2002;25:228–30.
60. DykstraDD, MendezA, ChappuisD, et al. Treatment of cervical dystonia and focal hand dystonia by high cervical continuously infused intrathecal baclofen: a report of 2 cases. Arch Phys Med Rehabil 2005;86:830–3.
61. KroinJS, AliaA, YorkM, PennRD. The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery 1993;33(2):226–30.
62. BrennanPM, WhittleIR. Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. Br J Neurosurg 2008;22:508–19.
63. PennRD, KroinJL. Continuous intrathecal baclofen for severe spasticity. Lancet 1985;2:125–7.
64. NarayanRK, LoubserPG, JankovicJJ, DonovanWH, BontkeCF. Intrathecal baclofen for intractable axial dystonia. Neurology 2001;41:1141–2.
65. PennRD, GianinoJM, YorkMM. Intrathecal baclofen for motor disorders. Mov Disord 1995:10;675–7.
66. AlbrightAL, BarryMJ, ShafronDH, FersonSS. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001;43:652–7.
67. PanouriasIG, ThemistocleousM, SakasDE. Intrathecal baclofen in current neuromodulatory practice: established indications and emerging applications. Acta Neurochirurgica. Supplement 2007;97(Pt 1):145–54.
68. KyriagisM, Grattan-SmithP, ScheinbergA, et al. Status dystonicus and Hallervorden-Spatz disease: treatment with intrathecal baclofen and pallidotomy. J Paediatr Child Health 2004;40:322–5.
69. KammC. Early onset torsion dystonia (Oppenheim’s dystonia). Orphanet J Rare Dis 2006;1:48–54.
70. MoreletA, Gagneux-LemoussuL, BrochotP, et al. Tonic dystonia: an uncommon complication of reflex sympathetic dystrophy syndrome. A review of five cases. Joint Bone Spine 2005;72:260–2.
71. ZunigaRE, PereraS, AbramSE. Intrathecal baclofen: a useful agent in the treatment of well-established complex regional pain syndrome. Reg Anesth Pain Med 2002;27:90–3.
72. LundS, LundbergA, VyklickyL. Inhibitatory action from the flexor reflex afferents on transmission to Ia afferents. Acta Physiol Scand 1965;64:345–55.
73. van HiltenBJ, van de BeekWJ, HoffJI, VoormolenJH, DelhaasEM. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. New Eng J Med 2000;343:625–31.
74. BhidayasiriR, TarsyD. Treatment of dystonia. Exp Rev Neurotherapeutics 2006;6:863–86.
75. HungSW, HamaniC, LozanoAM, et al. Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. Neurology 2007;68:457–9.
76. McLaughlinJ, BjornsonK, TemkinN, et al. Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Dev Med Child Neurol 2002;44:17–25.
77. TedroffK, LowingK, JacobsonDN, AstromE. Does loss of spasticity matter? A 10-year follow-up after selective dorsal rhizotomy in cerebral palsy. Dev Med Child Neurol 2011;53:724–9.
78. Fuller, D. Surgery in the management of spasticity. In BrashearA, ElovicE, eds. Spasticity Diagnosis and Management, New York: Demos Medical Publishing, 2011;243–70.
79. ReimersJ. Functional changes in the antagonists after lengthening the agonists in cerebral palsy. I triceps surae lengthening. Clin Orthop Relat Res 1990;253:30–4.
80. OmerGE, CapenDA. Proximal row carpectomy with muscle transfers for spastic paralysis. J Hand Surg Am 1976:1:197–204.
81. FehlingsD, NovakI, BerweckS, et al. Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. Eur J Neurol 2010;17:S(2)57–73.
82. LoveSC, NovakI, KentishM, et al. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol 2010;17:S(2)9–37.
83. LevyCE, GiuffridaC, RichardsL, et al. Botulinum toxin A, evidence-based exercise therapy, and constraint-induced movement therapy for upper-limb hemiparesis attributable to stroke: a preliminary study. Am J Phys Med Rehabil 2007;86:696–706.
84. SunSF, HsuCW, HwangCW, et al. Application of combined botulinum toxin type A and modified constraint-induced movement therapy for an individual with chronic upper-extremity spasticity after stroke. Phys Ther 2006;86:1387–97.
85. HoareB, ImmsC, CareyL, WasiakJ. Constraint-induced movement therapy in the treatment of the upper limb in children with hemiplegic cerebral palsy: a Cochrane systematic review. Clin Rehabil 2007;21:675–85.
86. GiovannelliM, BorrielloG, CastriP, et al. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 2007;21:331–7.
87. JohnsonCA, BurridgeJH, StrikePW, WoodDE, SwainID. The effect of combined use of botulinum toxin type A and functional electric stimulation in the treatment of spastic drop foot after stroke: a preliminary investigation. Arch Phys Med Rehabil 2004;85:902–9.
88. FarinaS, MiglioriniC, GandolfiM, et al. Combined effects of botulinum toxin and casting treatments on lower limb spasticity after stroke. Funct Neurol 2008;23:87–91.
89. VerplanckeD, SnapeS, SalisburyCF, JonesPW, WardAB. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil 2005;19:117–25.
90. BylNN, MckenzieA. Treatment effectiveness for patients with a history of repetitive hand use and focal hand dystonia: a planned, prospective follow-up study. J Hand Ther 2000;13:289–301.
91. ZeunerKE, Bara-JimenezW, NoguchiPS, et al. Sensory training for patients with focal hand dystonia. Ann Neurol 2002;51:593–8.
92. LanninNA, CusickA, McCluskeyA, HerbertRD. Effects of splinting on wrist contracture after stroke: a randomized controlled trial. Stroke 2006;38:111–16.
93. MarossezkyJE, GurkaJA, BaguleyIJ. Splinting poststroke: the jury is still out. Stroke 2008;39:e46.
94. KatalinicOM, HarveyLA, HerbertRD. Effectiveness of stretch for the treatment and prevention of contractures in people with neurological conditions: a systematic review. Phys Ther 2011;91:11–24.
95. AzherSN, JankovicJ.Camptocormia: pathogenesis, classification, and response to therapy. Neurology 2005;65(3):355–359.
96. GiladiN, MonigmanS.Botulinum toxin injections to one leg alleviate freezing of gait in a patient with Parkinson’s disease. Mov Disord 1997;12:1085–6.